These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9507885)

  • 1. Kidneys derived from mice transgenic for human complement blockers are protected in an in vivo model of hyperacute rejection.
    Lazzeri M; Mora M; Mulder LC; Marsicano G; Marinucci G; Boschi M; Bruzzone P; Alfani D; Cortesini R; Rossini M
    J Urol; 1998 Apr; 159(4):1364-9. PubMed ID: 9507885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion.
    McCurry KR; Kooyman DL; Diamond LE; Byrne GW; Logan JS; Platt JL
    Transplantation; 1995 Apr; 59(8):1177-82. PubMed ID: 7537395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
    Loveland BE; Milland J; Kyriakou P; Thorley BR; Christiansen D; Lanteri MB; Regensburg M; Duffield M; French AJ; Williams L; Baker L; Brandon MR; Xing PX; Kahn D; McKenzie IF
    Xenotransplantation; 2004 Mar; 11(2):171-83. PubMed ID: 14962279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic pigs expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor.
    Zhou CY; McInnes E; Copeman L; Langford G; Parsons N; Lancaster R; Richards A; Carrington C; Thompson S
    Xenotransplantation; 2005 Mar; 12(2):142-8. PubMed ID: 15693845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
    Díaz-Román TM; Mañez R; López-Pelaez E; Centeno A; Moscoso I; Pértegaz S; Doménech N
    Transpl Immunol; 2006 Aug; 16(2):125-30. PubMed ID: 16860716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human MCP and DHF double transgenic mice are protected from human complement attack in an in vivo model.
    Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Melli C; Bruzzone P; Alfani D
    Transplant Proc; 1996 Apr; 28(2):589. PubMed ID: 8623287
    [No Abstract]   [Full Text] [Related]  

  • 7. Complement regulatory proteins are expressed at low levels in embryonic human, wild type and transgenic porcine neural tissue.
    Harrower TP; Richards A; Cruz G; Copeman L; Dunnett SB; Barker RA
    Xenotransplantation; 2004 Jan; 11(1):60-71. PubMed ID: 14962294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The control of hyperacute rejection by genetic engineering of the donor species.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Eye (Lond); 1995; 9 ( Pt 2)():185-9. PubMed ID: 7556715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAE hybrid, on complement-mediated swine endothelial cell lysis.
    Miyagawa S; Shirakura R; Iwata K; Nakata S; Matsumiya G; Izutani H; Matsuda H; Terado A; Matsumoto M; Nagasawa S
    Transplantation; 1994 Oct; 58(7):834-40. PubMed ID: 7524206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic pigs expressing human decay-accelerating factor regulated by porcine MCP gene promoter.
    Murakami H; Nagashima H; Takahagi Y; Miyagawa S; Fujimura T; Toyomura K; Nakai R; Yamada M; Kurihara T; Shigehisa T; Okabe M; Seya T; Shirakura R; Kinoshita T
    Mol Reprod Dev; 2002 Mar; 61(3):302-11. PubMed ID: 11835575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human decay-accelerating factor expressed on rat hearts inhibits leukocyte adhesion.
    Verbakel CA; van Duikeren S; de Bruin RW; Marquet RL; IJzermans JN
    Transpl Int; 2003 Mar; 16(3):168-72. PubMed ID: 12664211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes.
    Wu G; Pfeiffer S; Schröder C; Zhang T; Nguyen BN; Kelishadi S; Atkinson JB; Schuurman HJ; White DJ; Azimzadeh AM; Pierson RN
    Xenotransplantation; 2007 Jan; 14(1):34-47. PubMed ID: 17214703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vivo model of hyperacute rejection: characterization and evaluation of the effect of transgenic human complement inhibitors.
    Mora M; Lazzer M; Marsicano G; Mulder LC; Carraresi L; Pieri A; Benanchi A; Grifoni D; Nuti S; Bruzzone P; Comporti M; Cortesini R; Rossini M
    Transgenic Res; 2000 Jun; 9(3):205-13. PubMed ID: 11032369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of human decay accelerating factor may protect pig lung from hyperacute rejection by human blood.
    Pierson RN; Pino-Chavez G; Young VK; Kaspar-Konig W; White DJ; Wallwork J
    J Heart Lung Transplant; 1997 Feb; 16(2):231-9. PubMed ID: 9059935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts.
    Lam TT; Hausen B; Hook L; Lau M; Higgins J; Christians U; Jacobsen W; Baluom M; Duthaler R; Katopodis A; Chavez G; Cozzi E; Harrison R; Schuurman HJ; Borie D; Morris RE
    Xenotransplantation; 2005 Jan; 12(1):20-9. PubMed ID: 15598270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo studies to prevent hyperacute rejection.
    Miyagawa S; Mikata M; Matsuda H; Ikawa M; Okabe M; Nagasawa S; Matsumoto M; Seya T; Shirakura R
    Transplant Proc; 1996 Apr; 28(2):1031-3. PubMed ID: 8623217
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of complement-mediated liver damage and protection in control and transgenic mice for human complement blockers MCP and DAF.
    Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Marinucci G; Melli CM; Bruzzone P; Alfani D; Cortesini R; Rossini M
    Transplant Proc; 1996 Feb; 28(1):127-9. PubMed ID: 8644143
    [No Abstract]   [Full Text] [Related]  

  • 19. Combining the hDAF transgene with the GP IIb/IIIa inhibitor tirofiban improves heart performance and reduces myocardial damage following hyperacute rejection in an ex vivo perfusion model.
    Brandl U; Erhardt M; Joeckle H; Michel S; Brenner P; Bittmann I; Roessle M; Mordstein V; Hammer C; Schmoeckel M; Reichart B
    Transplant Proc; 2005; 37(1):491-2. PubMed ID: 15808686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperacute rejection in ex vivo-perfused porcine lungs transgenic for human complement regulatory proteins.
    Pöling J; Oezkur M; Kogge K; Mengel M; Niemann H; Winkler M; Haverich A; Wiebe K
    Transpl Int; 2006 Mar; 19(3):225-32. PubMed ID: 16441772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.